Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Non-Current Debt (2016 - 2023)

Avalo Therapeutics' Non-Current Debt history spans 8 years, with the latest figure at $10.5 million for Q1 2023.

  • For Q1 2023, Non-Current Debt changed N/A year-over-year to $10.5 million; the TTM value through Mar 2023 reached $10.5 million, changed N/A, while the annual FY2022 figure was $13.5 million, 58.93% down from the prior year.
  • Non-Current Debt reached $10.5 million in Q1 2023 per AVTX's latest filing, down from $13.5 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $32.8 million in Q4 2021 to a low of $10.5 million in Q1 2023.
  • Average Non-Current Debt over 4 years is $16.9 million, with a median of $14.3 million recorded in 2019.
  • Peak YoY movement for Non-Current Debt: fell 0.68% in 2019, then tumbled 58.93% in 2022.
  • A 4-year view of Non-Current Debt shows it stood at $14.3 million in 2019, then surged by 130.33% to $32.8 million in 2021, then plummeted by 58.93% to $13.5 million in 2022, then dropped by 22.36% to $10.5 million in 2023.
  • Per Business Quant, the three most recent readings for AVTX's Non-Current Debt are $10.5 million (Q1 2023), $13.5 million (Q4 2022), and $16.5 million (Q3 2022).